This article is more than 5 years old. Information may no longer be current.

Trial of Opdivo in NSCLC ends 2 years early due to favorable outcomes

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

A randomized phase 3 trial designed to evaluate the novel agent nivolumab in previously treated patients with advanced, squamous cell non–small cell lung cancer ended 2 years early after the study met its primary endpoint.

Results showed patients assigned nivolumab (Opdivo, Bristol-Myers Squibb) — an anti–PD-1 checkpoint inhibitor — demonstrated longer OS than patients in the control arm, who underwent treatment with docetaxel.

The CheckMate-017 trial included 272 patients. Researchers randomly assigned patients to either nivolumab 3mg/kg intravenously every 2 weeks or docetaxel 75mg/m² intravenously every three weeks.

Final data from the study will be released at a later date.

The FDA approved nivolumab in December for the treatment of advanced melanoma. It is being evaluated for the treatment of renal cancer, head and neck cancers, bladder cancer and some blood cancers, including Hodgkin’s lymphoma.